Upstelda
Application withdrawn
The application for this medicine has been withdrawn
ustekinumab
MedicineHumanApplication withdrawn
French is available via eTranslation, the European Commission's machine translation service.
Translate to French | Important information about machine translation
- Application under evaluation
- Withdrawal of application
Overview
The applicant withdrew the marketing authorisation application for Upstelda (ustekinumab) on 22 March 2024. It was a duplicate of the application for another medicine, Wezenla, which EMA’s human medicines committee (CHMP) was evaluating in parallel, and which is not affected by this withdrawal.
Further details are included in the withdrawal letter.
Key facts
- Name of medicine
- Upstelda
- Active substance
- ustekinumab
- International non-proprietary name (INN) or common name
- ustekinumab
- Therapeutic area (MeSH)
- Psoriasis
- Arthritis, Psoriatic
- Crohn Disease
- Anatomical therapeutic chemical (ATC) code
- L04AC05
- EMA product number
- EMEA/H/C/006415
- Marketing authorisation applicant
- Amgen Technology (Ireland) UC
- Withdrawal of application
- 22/03/2024
News on Upstelda
This page was last updated on